Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

MLN-2704 granted fast track designation

Dec. 9, 2003

Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo

Dec. 9, 2003

Cetuximab enhances antitumor effects of cisplatin in late-stage clinical trial

Nov. 27, 2003

Medarex given go-ahead to begin phase I/II trial of MDX-214

Nov. 26, 2003

FDA lifts partial clinical hold on phase III trials of Oncophage

Nov. 26, 2003

Shionogi describes GM-CSF-like compounds with potential in cancer and neutropenia

Nov. 25, 2003

Therion evaluates Prostvac-VF in new phase II prostate cancer study

Nov. 25, 2003

Increased antitumor activity of pertuzumab combined with cytotoxic drugs in NSCLC models

Nov. 25, 2003

Promising preliminary phase I data for HER-2 Protein AutoVac vaccine

Nov. 24, 2003

New analysis of data from TNF-alpha AutoVac trial shows antibody levels

Nov. 20, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...